{"organizations": [], "uuid": "22aa80e93f4d6ed4cdc8d63f00a6ba8c91605320", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-xencor-doses-first-patient-in-phas/brief-xencor-doses-first-patient-in-phase-1-study-of-xmab18087an-antibody-for-treatment-of-neuroendocrine-tumors-and-gastrointestinal-stromal-tumors-idUSFWN1QC0Y5", "country": "US", "domain_rank": 408, "title": "BRIEF-Xencor Doses First Patient In Phase 1 Study Of Xmab®18087,An Antibody For Treatment Of Neuroendocrine Tumors And Gastrointestinal Stromal Tumors", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-22T15:10:00.000+02:00", "replies_count": 0, "uuid": "22aa80e93f4d6ed4cdc8d63f00a6ba8c91605320"}, "author": "", "url": "https://www.reuters.com/article/brief-xencor-doses-first-patient-in-phas/brief-xencor-doses-first-patient-in-phase-1-study-of-xmab18087an-antibody-for-treatment-of-neuroendocrine-tumors-and-gastrointestinal-stromal-tumors-idUSFWN1QC0Y5", "ord_in_thread": 0, "title": "BRIEF-Xencor Doses First Patient In Phase 1 Study Of Xmab®18087,An Antibody For Treatment Of Neuroendocrine Tumors And Gastrointestinal Stromal Tumors", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "antibody for treatment of neuroendocrine tumors", "sentiment": "neutral"}, {"name": "antibody for treatment of neuroendocrine tumors and gastrointestinal stromal tumors reuters", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "xencor inc", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Market News February 22, 2018 / 1:11 PM / Updated 3 minutes ago BRIEF-Xencor Doses First Patient In Phase 1 Study Of Xmab®18087,An Antibody For Treatment Of Neuroendocrine Tumors And Gastrointestinal Stromal Tumors Reuters Staff 1 Min Read Feb 22 (Reuters) - Xencor Inc: * XENCOR DOSES FIRST PATIENT IN PHASE 1 STUDY OF XMAB®18087 BISPECIFIC TUMOR TARGETING ANTIBODY FOR THE TREATMENT OF NEUROENDOCRINE TUMORS AND GASTROINTESTINAL STROMAL TUMORS * XENCOR INC SAYS “EXPECTS TO FILE INDS FOR 3 MORE BISPECIFIC ANTIBODIES FOR SOLID TUMORS THIS YEAR” Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-02-22T15:10:00.000+02:00", "crawled": "2018-02-22T15:18:26.017+02:00", "highlightTitle": ""}